Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 481

1.

Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS).

van Heijl M, van Lanschot JJ, Koppert LB, van Berge Henegouwen MI, Muller K, Steyerberg EW, van Dekken H, Wijnhoven BP, Tilanus HW, Richel DJ, Busch OR, Bartelsman JF, Koning CC, Offerhaus GJ, van der Gaast A.

BMC Surg. 2008 Nov 26;8:21. doi: 10.1186/1471-2482-8-21.

2.

Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial.

Meluch AA, Greco FA, Gray JR, Thomas M, Sutton VM, Davis JL, Kalman LA, Shaffer DW, Yost K, Rinaldi DA, Hainsworth JD.

Cancer J. 2003 Jul-Aug;9(4):251-60.

PMID:
12967135
3.

Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.

Kleinberg L, Knisely JP, Heitmiller R, Zahurak M, Salem R, Burtness B, Heath EI, Forastiere AA.

Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):328-34.

PMID:
12738305
5.

A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.

Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD, Roth JA.

Cancer. 2001 Jul 15;92(2):279-86.

PMID:
11466680
6.

Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study.

van Meerten E, Muller K, Tilanus HW, Siersema PD, Eijkenboom WM, van Dekken H, Tran TC, van der Gaast A.

Br J Cancer. 2006 May 22;94(10):1389-94.

7.

Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.

Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB Jr, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1484-93.

PMID:
15590179
8.

Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.

Murakami M, Kuroda Y, Okamoto Y, Kono K, Yoden E, Kusumi F, Hajiro K, Matsusue S, Takeda H.

Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1049-59.

PMID:
9539559
9.

Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.

Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA 3rd, Hainsworth JD.

J Clin Oncol. 2010 May 1;28(13):2213-9. doi: 10.1200/JCO.2009.24.8773. Epub 2010 Mar 29.

PMID:
20351330
10.

Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.

Choi N, Park SD, Lynch T, Wright C, Ancukiewicz M, Wain J, Donahue D, Mathisen D.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):111-22.

PMID:
15337546
11.

Preoperative chemoradiotherapy for esophageal or junctional cancer.

van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group.

N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088.

12.

A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer.

van de Schoot L, Romme EA, van der Sangen MJ, Creemers GJ, van Lijnschoten G, van Driel OJ, Rutten HJ, Nieuwenhuijzen GA.

Ann Surg Oncol. 2008 Jan;15(1):88-95. Epub 2007 Sep 26.

13.

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, van Laarhoven HW, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, Ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS study group.

Lancet Oncol. 2015 Sep;16(9):1090-8. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5.

PMID:
26254683
14.

Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.

Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J Jr, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):427-36.

PMID:
15380576
15.
16.

Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy.

Valencia Julve J, Alonso Orduña V, Escó Barón R, López-Mata M, Méndez Villamón A.

Clin Transl Oncol. 2006 Jan;8(1):22-30.

PMID:
16632436
17.

Neoadjuvant chemoradiation therapy in patients with surgically treated esophageal cancer.

Vermund H, Pories WJ, Hillard J, Wiley AL, Youngblood R.

Acta Oncol. 2001;40(5):558-65. Review.

PMID:
11669326
18.

Chemoradiation for esophageal cancer: institutional experience with three different regimens.

Courrech Staal EF, Aleman BM, van Velthuysen ML, Cats A, Boot H, Jansen EP, van Coevorden F, van Sandick JW.

Am J Clin Oncol. 2011 Aug;34(4):343-9. doi: 10.1097/COC.0b013e3181dbbafe.

PMID:
20562589
19.

Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06).

Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, von Moos R, Moosmann P, Montemurro M, Schneider PM, Rauch D, Gautschi O, Mingrone W, Widmer L, Inauen R, Brauchli P, Hess V.

J Clin Oncol. 2011 Feb 20;29(6):626-31. doi: 10.1200/JCO.2010.31.9715. Epub 2011 Jan 4.

PMID:
21205757
20.

Long-term results of neoadjuvant chemotherapy and combined chemoradiotherapy before surgery in the management of locally advanced oesophageal cancer: a single-centre experience.

Díaz R, Reynes G, Tormo A, de Juan M, Gironés R, Segura A, Aparicio J, Richart P, de la Cueva H, García J.

Clin Transl Oncol. 2009 Dec;11(12):835-41.

PMID:
20045790

Supplemental Content

Support Center